Anti Aβ antibody formulation

Details Anti Aβ antibody formulation Anti Aβ antibody formulation

2006-01-27

2009-12-22

Kolker, Daniel E. (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S152100

Reexamination Certificate

active

07635473

ABSTRACT:
The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.

REFERENCES:
patent: 5358708 (1994-10-01), Patel
patent: 5385887 (1995-01-01), Yim et al.
patent: 5688651 (1997-11-01), Solomon
patent: 5744132 (1998-04-01), Warne et al.
patent: 5770700 (1998-06-01), Webb et al.
patent: 5786180 (1998-07-01), Konig et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6270757 (2001-08-01), Warne
patent: 6372716 (2002-04-01), Bush et al.
patent: 6682735 (2004-01-01), Lowman et al.
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 6761888 (2004-07-01), Schenk
patent: 6787138 (2004-09-01), Schenk
patent: 6787139 (2004-09-01), Schenk
patent: 6787140 (2004-09-01), Schenk
patent: 6787143 (2004-09-01), Schenk
patent: 6787144 (2004-09-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6787637 (2004-09-01), Schenk et al.
patent: 6808712 (2004-10-01), Schenk
patent: 6818218 (2004-11-01), Schenk
patent: 6866849 (2005-03-01), Schenk
patent: 6866850 (2005-03-01), Schenk
patent: 6875434 (2005-04-01), Schenk
patent: 6890535 (2005-05-01), Schenk
patent: 6905686 (2005-06-01), Schenk
patent: 6913745 (2005-07-01), Schenk
patent: 6946135 (2005-09-01), Schenk
patent: 6962707 (2005-11-01), Schenk
patent: 6972127 (2005-12-01), Schenk
patent: 6982084 (2006-01-01), Schenk
patent: 7014855 (2006-03-01), Schenk
patent: 7179892 (2007-02-01), Basi et al.
patent: 7189819 (2007-03-01), Basi et al.
patent: 7256273 (2007-08-01), Basi et al.
patent: 2003/0054484 (2003-03-01), Fong et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 2003/0171556 (2003-09-01), Chae et al.
patent: 2003/0202972 (2003-10-01), Andya et al.
patent: 2004/0081657 (2004-04-01), Schenk
patent: 2004/0082762 (2004-04-01), Basi et al.
patent: 2004/0087777 (2004-05-01), Basi et al.
patent: 2004/0171815 (2004-09-01), Schenk et al.
patent: 2004/0171816 (2004-09-01), Schenk et al.
patent: 2004/0197324 (2004-10-01), Liu et al.
patent: 2004/0213800 (2004-10-01), Seubert et al.
patent: 2004/0219146 (2004-11-01), Schenk
patent: 2004/0247590 (2004-12-01), Schenk et al.
patent: 2004/0247591 (2004-12-01), Schenk et al.
patent: 2004/0265301 (2004-12-01), Schenk et al.
patent: 2004/0265308 (2004-12-01), Schenk
patent: 2005/0009150 (2005-01-01), Basi et al.
patent: 2005/0013815 (2005-01-01), Schenk
patent: 2005/0019328 (2005-01-01), Schenk
patent: 2005/0019330 (2005-01-01), Schenk
patent: 2005/0048049 (2005-03-01), Schenk
patent: 2005/0059591 (2005-03-01), Schenk et al.
patent: 2005/0059802 (2005-03-01), Schenk et al.
patent: 2005/0118651 (2005-06-01), Basi et al.
patent: 2005/0123544 (2005-06-01), Schenk et al.
patent: 2005/0142132 (2005-06-01), Schenk et al.
patent: 2005/0147613 (2005-07-01), Raso
patent: 2005/0158304 (2005-07-01), Schenk et al.
patent: 2005/0163788 (2005-07-01), Schenk
patent: 2005/0191292 (2005-09-01), Schenk
patent: 2005/0191314 (2005-09-01), Schenk
patent: 2005/0196399 (2005-09-01), Schenk et al.
patent: 2005/0249725 (2005-11-01), Schenk et al.
patent: 2005/0249727 (2005-11-01), Schenk
patent: 2005/0255122 (2005-11-01), Schenk
patent: 2006/0029611 (2006-02-01), Schenk
patent: 2006/0034858 (2006-02-01), Schenk
patent: 2006/0099206 (2006-05-01), Sinacore
patent: 2006/0153772 (2006-07-01), Jacobsen
patent: 2006/0160161 (2006-07-01), Pavlikova et al.
patent: 2006/0165682 (2006-07-01), Basi et al.
patent: 2006/0188512 (2006-08-01), Yednock et al.
patent: 2006/0193850 (2006-08-01), Warne et al.
patent: 2006/0198851 (2006-09-01), Basi et al.
patent: 2006/0210557 (2006-09-01), Luisi et al.
patent: 2006/0240486 (2006-10-01), Johnson-Wood et al.
patent: 2006/0257396 (2006-11-01), Jacobsen
patent: 2006/0280743 (2006-12-01), Basi et al.
patent: 2007/0082367 (2007-04-01), Godavarti et al.
patent: 2007/0134762 (2007-06-01), Arumugham et al.
patent: 2007/0154480 (2007-07-01), Schenk et al.
patent: 2007/0161088 (2007-07-01), Arumugham et al.
patent: 2007/0238154 (2007-10-01), Basi et al.
patent: 2008/0050367 (2008-02-01), Basi et al.
patent: 2008/0096818 (2008-04-01), Schenk et al.
patent: 2008/0145373 (2008-06-01), Arumugham et al.
patent: 2009/0155256 (2009-06-01), Black et al.
patent: 0597101 (1994-05-01), None
patent: 0758248 (1997-02-01), None
patent: 0758901 (1997-02-01), None
patent: 1 033 998 (2005-10-01), None
patent: WO 98/56418 (1998-12-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/27949 (1999-06-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO-01/05355 (2001-01-01), None
patent: WO-01/62801 (2001-08-01), None
patent: WO-02/46237 (2002-06-01), None
patent: WO-02/088306 (2002-11-01), None
patent: WO-02/088307 (2002-11-01), None
patent: WO 02/096457 (2002-12-01), None
patent: WO-03/009817 (2003-02-01), None
patent: WO-03/015691 (2003-02-01), None
patent: WO-03/016466 (2003-02-01), None
patent: WO-03/039485 (2003-05-01), None
patent: WO-03/077858 (2003-09-01), None
patent: WO-03/105894 (2003-12-01), None
patent: WO-2004/055164 (2004-07-01), None
patent: WO 2004/069182 (2004-08-01), None
patent: WO 2004/080419 (2004-09-01), None
patent: WO 2004/108895 (2004-12-01), None
patent: WO 2005/058940 (2005-06-01), None
patent: WO 2005/058941 (2005-06-01), None
patent: WO 2006/081587 (2006-08-01), None
patent: WO 2006/081587 (2006-08-01), None
patent: WO 2006/083689 (2006-08-01), None
U.S. Appl. No. 12/297,636, filed Jul. 2007, Lieberburg.
Bales, K.R. et al, “Administration of an Anti-AβFab Fragment to APPV717FTransgenic Mice Reduces Neuritic Plaque,” Abstract P4-396, p. S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based.
Bard, Frédérique et al, “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology,”PNAS, vol. 100(4):2023-2028 (2003).
Bard, Frédérique et al, “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in mouse model of Alzheimer disease,”Nature Medicine, vol. 6(8):916-919 (2000).
Bussièere, Thierry et al, “Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance,”American Journal of Pathology, vol. 165(3):987-995 (2004).
Games, Dora et al, “Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with Aβ1-42,”Ann. NY Acad. Sci., vol. 920:274-284 (2000).
Kajkowski, Eileen M. et al, “β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module,”The Journal of Biological Chemistry, vol. 276(22):18748-18756 (2001).
Zameer, Andleeb et al, “Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid-β: Potential Therapeutic for Alzheimer's Disease,”Abstract P4-420, p. S593, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based.
Vidanovic, D. et al, “Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation,”Die Pharmazie, vol. 58(6):399-404 (2003).
Wang, W. et al, “In

Affiliated with

Also associated with

Rating

Anti Aβ antibody formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti Aβ antibody formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti Aβ antibody formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4137442